U.S. Markets close in 4 hrs 34 mins

Today's Research Reports on Microbix Biosystems, Hemostemix, DiaMedica Therapeutics and Nuvo Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 21, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.com and get exclusive access to our numerous research reports and market updates.

The Market Edge Initiates Coverage on:

Microbix Biosystems Inc.
https://marketedgereport.com/report/MBX.TO/

Hemostemix Inc.
https://marketedgereport.com/report/HEM.V/

DiaMedica Therapeutics Inc.
https://marketedgereport.com/report/DMA.V/

Nuvo Pharmaceuticals Inc.
https://marketedgereport.com/report/NRI.TO/

Microbix Biosystems’ stocks had no change Tuesday, to close the day at $0.20. The stock recorded a trading volume of 57,000 shares, which was above its three months average volume of 57,780shares. In the last year, Microbix Biosystems' shares have traded in a range of 0.18 - 0.34. The share price has gained 11.11% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.21 is lower than its 200-day moving average of $0.26. Shares of Microbix Biosystems have fallen approximately 35.48 percent year-to-date.

Access The Market Edge's Microbix Biosystems Inc. Research Report:
https://marketedgereport.com/report/MBX.TO/

On Tuesday, shares of Hemostemix recorded a trading volume of 61,475 shares, which was below the three months average volume of 216,045 shares. The stock ended the day 18.52% lower at $0.11. The share price has fallen 21.43% from its 52 week high with a 52 week trading range of 0.05 - 0.14. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.11 is greater than its 200-day moving average of $0.08. Shares of Hemostemix have gained approximately 57.14 percent year-to-date.

Access The Market Edge's Hemostemix Inc. Research Report:
https://marketedgereport.com/report/HEM.V/

DiaMedica Therapeutics’ stock moved 8.64% lower Tuesday, to close the day at $5.71. The stock recorded a trading volume of 15,475 shares, which was above its three months average volume of 7,409 shares. In the last year, DiaMedica Therapeutics' shares have traded in a range of 4.20 - 18.00. The share price has gained 35.95% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $9.42 is lower than its 200-day moving average of $11.19. Shares of DiaMedica Therapeutics have fallen approximately 1.55 percent year-to-date.

Access The Market Edge's DiaMedica Therapeutics Inc. Research Report:
https://marketedgereport.com/report/DMA.V/

On Tuesday, shares of Nuvo Pharmaceuticals recorded a trading volume of 100 shares, which was below the three months average volume of 5,834 shares. The stock ended the day 1.46% lower at $2.70. The share price has fallen 34.62% from its 52 week high with a 52 week trading range of 2.55 - 4.13. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.74 is lower than its 200-day moving average of $2.80. Shares of Nuvo Pharmaceuticals have fallen approximately 27.03 percent year-to-date.

Access The Market Edge's Nuvo Pharmaceuticals Inc. Research Report:
https://marketedgereport.com/report/NRI.TO/

Our Actionable Research on Microbix Biosystems Inc. (TSX : MBX.TO ), Hemostemix Inc. (TSXV : HEM.V ), DiaMedica Therapeutics Inc. (TSXV : DMA.V ) and Nuvo Pharmaceuticals Inc. (TSX : NRI.TO ) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport